Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST
Posts From the monthly archives: "June 2014"

We decided to mine the biomarkers being used in clinical trials for interesting test development opportunities, and we began with Oncology as the first therapeutic area to explore. Our basic methodology was to identify biomarkers that are in regular (and hopefully growing) use in Oncology, and that are also being used in at least one…(Read More)

While multi-biomarker approaches are certainly going to become more common (key quote: “We really are moving away from this one drug, one biomarker, one companion diagnostic,” Dr Richard Pazdur, FDA’s oncology chief), this article identifies one key challenge, and that is sample scarcity. Multi-biomarker really does need to be true multiplexing, especially…(Read More)

This article provides a nice summary of progress in using biomarkers to help treat cancer. One of the key takeaways is how much potential there is to understand the precise differences in tumors, and how different drugs will affect each of them. The article references “matrix style” trials as a way to get at this…(Read More)

NanoString will utilize IP from a 20-gene expression assay developed by the Lymphoma/Leukemia Molecular Profiling Project (LLMP) to develop a companion diagnostic test to support clinical validation of Celgene’s REVLIMID®. NanoString could receive up to $45 million in payments under the deal. Company press release…(Read More)